نتائج البحث - Fritz Offner

تنقيح النتائج
  1. 1
    Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies

    Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies حسب Dorien Clarisse, Fritz Offner, Karolien De Bosscher

    منشور في 2020
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATION

    GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATION حسب Carmelo Carlo‐Stella, Martin Hutchings, Fritz Offner, E. Mulvihill, James Relf, Ben Byrne, Linda Lundberg, Michael Dickinson

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

    Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refrac... حسب John P. Leonard, Marek Trněný, Fritz Offner, Jiří Mayer, Huilai Zhang, Grzegorz S. Nowakowski, Phillip Scheinberg, Argyrios Gkasiamis, Joanna Mikita-Geoffroy, Everton Rowe, John G. Gribben

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma

    Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma حسب Ioanna Papandreou, Nicholas Denko, Michael F. Olson, Heleen Van Melckebeke, Sofie Lust, Arvin B. Tam, David E. Solow-Cordero, Donna M. Bouley, Fritz Offner, Maho Niwa, Albert C. Koong

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

    Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL حسب Fritz Offner, Olga Samoilova, Evgenii A. Osmanov, Hyeon‐Seok Eom, Max S. Topp, João Raposo, Viacheslav Pavlov, Deborah Ricci, Shalini Chaturvedi, Eugene Zhu, Helgi van de Velde, Christopher Enny, Aleksandra Rizo, Burhan Ferhanoğlu

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

    Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study حسب Marinus H. J. van Oers, Kazimierz Kuliczkowski, Lukáš Smolej, Mario Petrini, Fritz Offner, Sebastian Grosicki, Mark-David Levin, Ira Gupta, Jennifer L. Phillips, Vanessa C. Williams, Stephanie Manson, Steen Lisby, Christian H. Geisler

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study

    Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study حسب Vincent Ribrag, Won Seog Kim, Réda Bouabdallah, Soon Thye Lim, Bertrand Coiffier, Árpád Illés, Bernard Lemieux, Martin J.S. Dyer, Fritz Offner, Zakia Felloussi, Ioana Kloos, Ying Luan, Remus Vezan, Thorsten Graef, Franck Morschhauser

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY

    S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY حسب Fritz Offner, O. Decaux, Cyrille Hulin, Sébastien Anguille, Anne Sophie Michallet, Luciano J. Costa, Cyrille Touzeau, Kevin Boyd, Deeksha Vishwamitra, Yue Guo, Zhuolu Niu, Julie S. Larsen, Lingling Chen, Arnob Banerjee, Jenna D. Goldberg, Jeffrey Matous

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Phase <scp>IA</scp>/<scp>II</scp>, multicentre, open‐label study of the <scp>CD</scp>40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐<scp>H</scp>odgkin or <scp>H</scp>odgkin lymphoma

    Phase <scp>IA</scp>/<scp>II</scp>, multicentre, open‐label study of the <scp>CD</scp>40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐<scp>H</scp... حسب Michelle A. Fanale, Sarit Assouline, John Kuruvilla, Philippe Solal‐Céligny, Dae Seog Heo, Gregor Verhoef, Paolo Corradini, Jeremy S. Abramson, Fritz Offner, Andreas Engert, Martin J.S. Dyer, D. Carreon, Brett Ewald, Johan Baeck, Anas Younes, Arnold S. Freedman

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

    Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma حسب Martin Hutchings, Carmelo Carlo‐Stella, Emmanuel Bachy, Fritz Offner, Franck Morschhauser, Michael Crump, Gloria Iacoboni, Anna Sureda, Joaquín Martínez‐López, Linda Lundberg, Mark Dixon, D. Callejo, James Relf, David Carlile, Emily Piccione, Kathryn Humphrey, Michael Dickinson

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

    Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms حسب Hervé Ghesquières, Guillaume Cartron, John F. Seymour, Marie‐Hélène Delfau‐Larue, Fritz Offner, Pierre Soubeyran, Aurore Perrot, Pauline Brice, Réda Bouabdallah, Anne Sonet, Jehan Dupuis, Olivier Casasnovas, John Catalano, Alain Delmer, Fabrice Jardin, Aurélie Verney, Peggy Dartigues, Gilles Salles

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

    A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma حسب Markus Hansson, Peter Gimsing, Ashraf Badros, Titti Martinsson Niskanen, Hareth Nahi, Fritz Offner, Morten Salomo, Elisabeth Sonesson, Morten Mau‐Sørensen, Yvonne Stenberg, Annika Sundberg, Ingrid Teige, Jan Van Droogenbroeck, Stina Wichert, Maurizio Zangari, Björn Frendéus, Magnus Korsgren, Martine Poelman, Guido Tricot

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

    Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study حسب Simon Rule, Wojciech Jurczak, Mats Jerkeman, C. Rusconi, Marek Trněný, Fritz Offner, Dolores Caballero, Cristina João, Mathias Witzens‐Harig, Georg Heß, Isabelle Bence‐Bruckler, Seok‐Goo Cho, Catherine Thiéblemont, Wangchi Zhou, Todd Henninger, Judith D. Goldberg, Jessica Vermeulen, Martin Dreyling

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    IBRUTINIB VS TEMSIROLIMUS: THREE‐YEAR FOLLOW‐UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN‐LABEL RAY STUDY

    IBRUTINIB VS TEMSIROLIMUS: THREE‐YEAR FOLLOW‐UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN‐LABEL RAY STUDY حسب Simon Rule, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Alves da Silva, C. Rusconi, Marek Trněný, Fritz Offner, Dolores Caballero, Cristina João, Mathias Witzens‐Harig, Georg Heß, I. Bence‐Bruckler, S. Cho, Catherine Thiéblemont, Wangchi Zhou, Todd Henninger, Jeffrey L. Goldberg, Jessica Vermeulen, Martin Dreyling

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

    Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia حسب Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steven Coutré, Claire Dearden, Sebastian Grosicki, Helen O. McCarthy, Jianyong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szőke, Thomas J. Kipps, Paolo Ghia

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma حسب Torben Plesner, Simon J. Harrison, Hang Quach, Cindy Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick J. Twomey, Voleak Choeurng, Junyi Li, Robert L. Hendricks, Shannon M. Ruppert, Teiko Sumiyoshi, Karen K. Miller, Eunpi Cho, Fredrik Schjesvold

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

    Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial حسب Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiřı́ Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Sven de Vos, Michael Crump, Ofer Shpilberg, Dixie‐Lee Esseltine, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Yusri Elsayed, Pier Luigi Zinzani

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

    Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies حسب Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Marie Maerevoet, Jean‐Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, Jean‐Marie Michot, Karen Silence, Anna Hultberg, Domenica Gandini, Hans de Haard, Vincent Ribrag, Marc Peeters, Alain Thibault, Nicolas Leupin, Ahmad Awada

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

    PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPH... حسب Catherine Thiéblemont, John P. Leonard, Marek Trněný, Koji Izutsu, Nathan Fowler, Xin Hong, H. Zhang, Fritz Offner, Adriana Scheliga, GS Nowakowski, Antonio Pinto, Francesca Re, Laura Fogliatto, Phillip Scheinberg, Ian W. Flinn, C. Moreira, M. S. Czuczman, Stacey Kalambakas, Pierre Fustier, Changping Wu, JG Gribben

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

    Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study حسب Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven Coutré, Stephen Devereux, Sebastian Grosicki, Helen O. McCarthy, David Simpson, Fritz Offner, Carol Moreno, Sandra Dai, Indu Lal, James P. Dean, Thomas J. Kipps

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: